Conference Papers in Medicine

Volume 2013 (2013), Article ID 583175, 5 pages

http://dx.doi.org/10.1155/2013/583175

Conference Paper

Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction: Diagnostic Implications

O. Hammarsten

Department of Clinical Chemistry and Transfusion Medicine, Bruna stråket 16, Sahlgrenska Academy at The University of Gothenburg, 413 45 Gothenburg, Sweden

Received 15 January 2013; Accepted 1 April 2013

Academic Editors: A. Bellou, E. Giannitsis, C. Hamm, M. Möckel, and J. Searle

This Conference Paper is based on a presentation given by O. Hammarsten at “Clinical Decisions in Acute Patients: ACS–POCT–Hypertension and Biomarkers” held from 19 October 2012 to 20 October 2012 in Berlin, Germany.

Copyright © 2013 O. Hammarsten. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Changes in cardiac troponin (cTn) levels are often evaluated when myocardial infarction (MI) is suspected. The change in the troponin level required for diagnosis is being debated but should exceed the natural biological variation according to current guidelines. Despite this, several reports show that MI patients often present at the emergency ward with relatively stable cTn elevations. In this review we discuss the potential problem using a small cTn change as a way to exclude MI and also provide a possible solution to this diagnostic problem using long-term cTn change.

1. Introduction

When the electrocardiogram (ECG) is inconclusive, the diagnosis of myocardial infarction often involves monitoring of the level of and change in the heart damage biomarkers cardiac troponin T (cTnT) or cardiac troponin I (cTnI) [1–3]. The introduction of high-sensitive cardiac troponin (cTn) assays and the lowering of the diagnostic threshold to the 99th cTn percentile have increased the number of patients presenting with an elevated cTn level that needs further assessment. This is especially prevalent among older emergency room patients, where 36–50% of patients over 65–70 years of age without myocardial infarction (MI) present with an cTnT level above the 99th percentile [4, 5]. In these instances, the change in the cTn level is often evaluated during 3–6 hours and sometimes up to 24 hours [2, 6]. A few hours after cardiac ischemia, the levels of cTn start to increase and reache a plateau phase after 10–15 hour followed by a slow decline [7]. The logic behind evaluating the cTn change is to provide cTn-level-independent evidence of acute myocardial damage. It is often considered that MI can be excluded if the cTn change remains below 20% [1], a criterion based on the analytical imprecision of the cTn assays [1, 2, 8]. On the other hand, the diagnosis of MI relies on the ability to observe a significant cTn rise and/or falling pattern [2]. The relevant cTn change required for the MI diagnosis is still being debated but must exceed the natural biological variation according to the current European guidelines [6]. There are, however, several reports indicating that many patients with MI present with elevated cTn levels that remain stable during a 1–6 h evaluation period (Table 1). These findings question the use of a small cTn change as a way to exclude the MI diagnosis.

Table 1: Studies reporting cTn change in patients with myocardial infarction.

Study cohort
Number of patients in study
Number of patients with MI
Only NSTEMI
Percent of MI patients with <20–25% cTn change during study
Percent of MI patients with <30% cTn change during study
Percent of MI patients with <50–60% cTn change during study
Time during which cTn change was evaluated in the study (h)
cTn change recorded during the hospital stay required for diagnosis
cTn assay used
Symptom time (h)b
Reference

Suspected ACS in ER
332
110
No
28%
NR
38%
9.4
No
Roche cobas/E170 hs-cTnT
4
[16]

Suspected ACS in ER and patients admitted to the hospital
784
165
Yes
25%
NR
47%
6
>20% or >5 ng/L
Roche cobas/E170 hs-cTnT
NR*
[14]

Suspected ACS in ER
454
142
No
5%#
NR
11%
24
>20%
Siemens Stratus CS TnI

[17]

Suspected ACS in ER
381
51
No
25%
25%
NR
6
>20%
Ortho VITROS TnI
3.9
[19]

Suspected ACS in ER
939
200
Yes
51%
0.62
NR
2
No
Roche cobas/E170 hs-cTnT
NR
[18]

Suspected ACS in ER
1818
413
No
23%
27%
33%
3
>20%
Abbott Architect STAT high sensitive TnI
4.3
[20]

Suspected ACS in ER
590
65
Yes
36%
NR
50%
2
>4.2 ng/L
Roche cobas/E170 hs-cTnT

[13]

NR: not reported. ACS: acute coronary syndrome. MI: myocardial infarction. CCU: coronary care unit. ER: emergency room. NSTEMI: non ST-elevation myocardial infarction. Median time since start of symptom at baseline in hours. Median symptom time 20 h if <20% change, and median symptom time 12 h if >20% change. Symptom time <8 h or <12 h respectively required for inclusion in study. 16% had a <20% cTnI change at 6 h.

2. Normal Levels of Cardiac Troponin Change

The natural biological variation of cTn levels has been extensively studied in populations without acute myocardial damage (reviewed in [9]). The cTn change can be expressed as the relative cTn change, the percentage of change from a baseline sample, or absolute change, the difference in ng/L from a baseline sample. Relative cTn change is similar at different cTn levels whereas the absolute cTn change increases with the cTn level [4]. Therefore, normal values of relative cTn change can be reported as single value whereas relevant normal values of absolute cTn change must take the individuals baseline cTn level into consideration.

The normal values of relative cTn change are generally reported as reference change values (RCVs), the range of relative cTn change that includes 95% of all observations in the study population. The RCV for cTnI during a few hours of observation in a healthy population was a rising pattern of 46% or falling pattern of 32% [10]. The RCV for cTnT in a healthy population was 85% [11]. In patients with stable coronary disease [9] or patients admitted due to noncardiac chest pain [12], the RCV for TnI was similar to what was found in healthy subjects (rising pattern of 54–76% and falling pattern of 35–41%). The RCV for cTnT in these studies was actually lower than what was found in healthy subjects (rising pattern of 26–46% and falling pattern of 21–32%) probably due to analytical issues in the previous study [11]. Among patients in a coronary care unit without myocardial infarction, the median relative cTnT change was around 10% and the 97.5th percentile, the upper reference value of relative TnT change, was around 60% [4]. Therefore, relative cTn change above 40–60% is above the natural biological variation and could therefore be regarded as pathological.

The normal value of relative cTn change has not been examined to the same extent [12] as relative changes are different at different cTn levels [4]. However, the absolute cTn change that optimally separates patients with or without MI has been reported. An absolute cTnT change of 7 ng/L during 2 hours of observation [13] and 9 ng/L under six hours of observation [14] was shown to have a superior ability to identify patients with MI compared with the relative cTn change. However, these single cut-off points provided less diagnostic precision among patients with stable cTn elevations [14]. An attempt to find cTn level-stratified cutoff points for absolute cTnT change indicated that 5 ng/L optimally separated patients withMI among suspected acute coronary syndrome patients with a baseline cTnT level below 40 ng/L [14]. Similarly, an diagnostic algorithm derived from the APACE study shows that a one-hour absolute cTnT change of 3 ng/L identified all patients with MI presenting with a baseline cTnT level below 12 ng/L whereas an absolute change of 5 ng/L was needed when the baseline TnT level was between 12 and 52 ng/L [15]. Therefore, when the baseline cTn level is low, absolute cTnT changes above 3–5 ng/L are above the natural biological variation and could therefore be regarded as pathological. When the baseline cTn level is elevated, as often seen in patients with renal failure, heart failure, and old age, the absolute cTn change that optimally separates patients with and without acute myocardial injury is less clear.

3. Cardiac Troponin Change in Patients with MI

The distribution of relative cTn changes in patients with MI have been reported in several studies [13, 14, 16–20] (Table 1). However, since a change in the cTn level is often involved in the MI diagnosis, many of these reports have introduced a circular argument in the study group and thereby reduced their ability to examine the extent of small troponin changes in patients with MI. To establish the true distribution of cTn change in MI patients, a prospective study is needed where all patients are subjected to angiography, imaging, and functional examinations to obtain cTn-independent evidence of acute myocardial damage of ischemic origin, a study that is yet to be performed. Despite this potential bias in the current studies they often show that over one fifth of patients with MI have short-time cTn changes well within the normal range (Table 1). Although most of the MI patients eventually developed a cTn change above 20% during the hospital stay, as this was often required for the diagnosis (Table 1), the studies indicate that many patients with MI present with stable cTn elevations during the first few hours [14]. The overlap in cTn change among patients with and without MI results in a low diagnostic precision when short-time relative cTn changes are used in the MI diagnosis [13, 16, 20]. These findings questions the requirement to detect a significant rise and/or fall in cTn levels during the hospital stay as an essential part of the diagnosis of MI. Importantly, these data also indicate that it is not safe to exclude MI based on small cTn change recorded during a few hours.

4. The Pathophysiology of MI with Small cTn Change

An important question is why small relative cTn changes seem to be so common in patients with MI? Even if direct evidence is lacking, the available information suggests that small cTn changes are due to presentation late in the infarction process. A small relative cTn change is positively correlated with long symptom time and presentation with high cTn levels at baseline [14] indicating that many MI patients with small cTn changes present close to the plateau phase of the cTn release or later. The possibility that many patients with MI are late presenters fits with the pathophysiology of MI. Close to 50% of the thrombi extracted from coronary arteries in patients with ECG-positive MI show histological signs of being several days old [21, 22], and 75% of all ruptured coronary plaques assigned as the culprit lesion show signs of having ruptured before [23]. In addition, 30–40% of all MIs found in prospective studies are silent, most likely because of diffuse symptoms [24, 25] that, in turn, can be explained by the fact that 70% of ischemic events detected by ECG do not result in chest pain [26].

5. The Use of Long-Term cTn Change in the Diagnosis of MI

Taken together the existing data questions the use of a significant cTn change recorded during the hospital stay as a mandatory part of the MI diagnosis and as a way to rule out MI. It is possible that cTn change evaluated at an outpatient checkup after the event could be an alternative way to diagnose MI. This way of confirming the diagnosis could be applied if the suspicion of MI is low or moderate, the in-hospital cTn levels remain only moderately elevated, and the cTn change is small. In these instances it is possible that the patient could receive a tentative MI diagnosis until a large relative cTn change can be recorded after a week or two at an outpatient checkup. If these patients, as appropriate after evaluation of the bleeding risk, were started on the same secondary prevention scheme as patients with a firm MI diagnosis, this procedure would add diagnostic precision with little risk to the patient. We are currently evaluating some aspects of this procedure.

Abbreviations

MI: | Myocardial infarction
cTn: | Cardiac troponin T
cTnT: | Cardiac troponin T
cTnI: | Cardiac troponin I
NSTEMI: | Non-ST-elevation myocardial infarction.

Acknowledgments

This work was supported by the Swedish Cancer Society, the Swedish Research Council, the Swedish Pain Foundation (SSF), the Assar Gabrielsson Cancer Research Foundation, and by LUA/ALF Funding at the Sahlgrenska University Hospital.

References

K. Thygesen, J. Mair, E. Giannitsis et al., “How to use high-sensitivity cardiac troponins in acute cardiac care,” European Heart Journal, vol. 33, no. 18, pp. 2252–2257, 2012.

K. Thygesen, J. S. Alpert, A. S. Jaffe et al., “Third universal definition of myocardial infarction,” Circulation, vol. 126, pp. 2020–2035, 2012.

K. Thygesen, J. Mair, H. Katus et al., “Recommendations for the use of cardiac troponin measurement in acute cardiac care,” European Heart Journal, vol. 31, no. 18, pp. 2197–2204, 2010.

O. Hammarsten, M. L. Fu, R. Sigurjonsdottir et al., “Troponin t percentiles from a random population sample, emergency room patients and patients with myocardial infarction,” Clinical Chemistry, vol. 58, no. 3, pp. 628–637, 2012.

M. Reiter, R. Twerenbold, T. Reichlin et al., “Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays,” European Heart Journal, vol. 32, no. 11, pp. 1379–1389, 2011.

P. G. Steg, S. K. James, D. Atar et al., “Esc guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation,” European Heart Journal, vol. 33, no. 20, pp. 2569–2619, 2012.

H. A. Katus, A. Remppis, T. Scheffold, K. W. Diederich, and W. Kuebler, “Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction,” American Journal of Cardiology, vol. 67, no. 16, pp. 1360–1367, 1991.

A. H. B. Wu, A. S. Jaffe, F. S. Apple et al., “National academy of clinical biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure,” Clinical Chemistry, vol. 53, no. 12, pp. 2086–2096, 2007.

A. M. Nordenskjold, H. Ahlstrom, K. M. Eggers et al., “Short- and long-term individual variation in cardiac troponin in patients with stable coronary artery disease,” Clinical Chemistry, vol. 59, no. 2, pp. 401–409, 2013.

A. H. B. Wu, A. L. Quynh, J. Todd, J. Moecks, and F. Wians, “Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice,” Clinical Chemistry, vol. 55, no. 1, pp. 52–58, 2009.

V. C. Vasile, A. K. Saenger, J. M. Kroning, and A. S. Jaffe, “Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay,” Clinical Chemistry, vol. 56, no. 7, pp. 1086–1090, 2010.

V. Scharnhorst, K. Krasznai, M. van 't Veer, and R. H. Michels, “Variation of cardiac troponin i and t measured with sensitive assays in emergency department patients with noncardiac chest pain,” Clinical Chemistry, vol. 58, no. 8, pp. 1208–1214, 2012.

T. Reichlin, A. Irfan, R. Twerenbold et al., “Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction,” Circulation, vol. 124, no. 2, pp. 136–145, 2011.

M. Mueller, M. Biener, M. Vafaie et al., “Absolute and relative kinetic changes of high-sensitivity cardiac troponin t in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome,” Clinical Chemistry, vol. 58, no. 1, pp. 209–218, 2012.

T. Reichlin, C. Schindler, B. Drexler et al., “One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin t,” Archives of Internal Medicine, vol. 172, no. 16, pp. 1211–1218, 2012.

S. J. Aldous, C. M. Florkowski, I. G. Crozier et al., “Comparison of high sensitivity and contemporary troponin assays for the early detection of acute myocardial infarction in the emergency department,” Annals of Clinical Biochemistry, vol. 48, no. 3, pp. 241–248, 2011.

K. M. Eggers, A. S. Jaffe, P. Venge, and B. Lindahl, “Clinical implications of the change of cardiac troponin I levels in patients with acute chest pain-an evaluation with respect to the Universal Definition of Myocardial Infarction,” Clinica Chimica Acta, vol. 412, no. 1-2, pp. 91–97, 2011.

S. J. Aldous, A. M. Richards, L. Cullen, and M. P. Than, “Early dynamic change in high-sensitivity cardiac troponin T in the investigation of acute myocardial infarction,” Clinical Chemistry, vol. 57, no. 8, pp. 1154–1160, 2011.

F. S. Apple, L. A. Pearce, S. W. Smith, J. M. Kaczmarek, and M. M. Murakami, “Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events,” Clinical Chemistry, vol. 55, no. 5, pp. 930–937, 2009.

T. Keller, T. Zeller, F. Ojeda et al., “Serial changes in highly sensitive troponin i assay and early diagnosis of myocardial infarction,” Journal of the American Medical Association, vol. 306, no. 24, pp. 2684–2693, 2011.

S. Y. Choi and G. S. Mintz, “What have we learned about plaque rupture in acute coronary syndromes?” Current Cardiology Reports, vol. 12, no. 4, pp. 338–343, 2010.

S. Z. H. Rittersma, A. C. Van Der Wal, K. T. Koch et al., “Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention,” Circulation, vol. 111, no. 9, pp. 1160–1165, 2005.

A. P. Burke, F. D. Kolodgie, A. Farb et al., “Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression,” Circulation, vol. 103, no. 7, pp. 934–940, 2001.

A. de Torbal, E. Boersma, J. A. Kors et al., “Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study,” European Heart Journal, vol. 27, no. 6, pp. 729–736, 2006.

W. B. Kannel and R. D. Abbott, “Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study,” New England Journal of Medicine, vol. 311, no. 18, pp. 1144–1147, 1984.

D. D. Gutterman, “Silent myocardial ischemia,” Circulation Journal, vol. 73, no. 5, pp. 785–797, 2009.